Cargando…

Development and Validation of a Prognostic Model for Multi-Drug-Resistant Non-Hospital-Acquired Bloodstream Infection

Bloodstream infections (BSI) are an increasing cause of admissions to hospitals. Non-hospital-acquired BSI are defined by blood cultures that are positive less than 48 hours after admission, but a relevant difference exists between community-acquired and healthcare-associated (HCA) BSI in terms of r...

Descripción completa

Detalles Bibliográficos
Autores principales: Pivetta, Emanuele, Corcione, Silvia, Peasso, Paolo, Cara, Irene, Capodanno, Alberto, Brussino, Andrea, Petitti, Paolo, Galli, Eleonora, Galmozzi, Maddalena, Ghisetti, Valeria, Cavallo, Rossana, Aprà, Franco, Lupia, Enrico, De Rosa, Francesco Giuseppe, Montrucchio, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295786/
https://www.ncbi.nlm.nih.gov/pubmed/37370274
http://dx.doi.org/10.3390/antibiotics12060955
_version_ 1785063504172023808
author Pivetta, Emanuele
Corcione, Silvia
Peasso, Paolo
Cara, Irene
Capodanno, Alberto
Brussino, Andrea
Petitti, Paolo
Galli, Eleonora
Galmozzi, Maddalena
Ghisetti, Valeria
Cavallo, Rossana
Aprà, Franco
Lupia, Enrico
De Rosa, Francesco Giuseppe
Montrucchio, Giuseppe
author_facet Pivetta, Emanuele
Corcione, Silvia
Peasso, Paolo
Cara, Irene
Capodanno, Alberto
Brussino, Andrea
Petitti, Paolo
Galli, Eleonora
Galmozzi, Maddalena
Ghisetti, Valeria
Cavallo, Rossana
Aprà, Franco
Lupia, Enrico
De Rosa, Francesco Giuseppe
Montrucchio, Giuseppe
author_sort Pivetta, Emanuele
collection PubMed
description Bloodstream infections (BSI) are an increasing cause of admissions to hospitals. Non-hospital-acquired BSI are defined by blood cultures that are positive less than 48 hours after admission, but a relevant difference exists between community-acquired and healthcare-associated (HCA) BSI in terms of risk of multidrug resistance (MDR). We planned a retrospective study in three different cohorts in order to develop and to temporally and spatially validate an easy and rapid prognostic model for identifying MDR non-hospital-acquired (non-HA) BSI. The pathogens most involved in BSI are Staphylococcus spp. and Escherichia coli, responsible for about 75% of all MDR isolated. The model includes age, gender, long-term care facility admission, immunocompromise, any recent invasive procedures and central line placement, recent intravenous treatment and antibiotic treatment. It shows an acceptable performance, especially for intermediate probabilities of MDR infection, with a C-index of 70%. The model was proposed in a nomogram that could allow better targeting of antibiotic therapy for non-HA BSI admitted in hospital. However, it should be further validated to determine its applicability in other populations.
format Online
Article
Text
id pubmed-10295786
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102957862023-06-28 Development and Validation of a Prognostic Model for Multi-Drug-Resistant Non-Hospital-Acquired Bloodstream Infection Pivetta, Emanuele Corcione, Silvia Peasso, Paolo Cara, Irene Capodanno, Alberto Brussino, Andrea Petitti, Paolo Galli, Eleonora Galmozzi, Maddalena Ghisetti, Valeria Cavallo, Rossana Aprà, Franco Lupia, Enrico De Rosa, Francesco Giuseppe Montrucchio, Giuseppe Antibiotics (Basel) Article Bloodstream infections (BSI) are an increasing cause of admissions to hospitals. Non-hospital-acquired BSI are defined by blood cultures that are positive less than 48 hours after admission, but a relevant difference exists between community-acquired and healthcare-associated (HCA) BSI in terms of risk of multidrug resistance (MDR). We planned a retrospective study in three different cohorts in order to develop and to temporally and spatially validate an easy and rapid prognostic model for identifying MDR non-hospital-acquired (non-HA) BSI. The pathogens most involved in BSI are Staphylococcus spp. and Escherichia coli, responsible for about 75% of all MDR isolated. The model includes age, gender, long-term care facility admission, immunocompromise, any recent invasive procedures and central line placement, recent intravenous treatment and antibiotic treatment. It shows an acceptable performance, especially for intermediate probabilities of MDR infection, with a C-index of 70%. The model was proposed in a nomogram that could allow better targeting of antibiotic therapy for non-HA BSI admitted in hospital. However, it should be further validated to determine its applicability in other populations. MDPI 2023-05-24 /pmc/articles/PMC10295786/ /pubmed/37370274 http://dx.doi.org/10.3390/antibiotics12060955 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pivetta, Emanuele
Corcione, Silvia
Peasso, Paolo
Cara, Irene
Capodanno, Alberto
Brussino, Andrea
Petitti, Paolo
Galli, Eleonora
Galmozzi, Maddalena
Ghisetti, Valeria
Cavallo, Rossana
Aprà, Franco
Lupia, Enrico
De Rosa, Francesco Giuseppe
Montrucchio, Giuseppe
Development and Validation of a Prognostic Model for Multi-Drug-Resistant Non-Hospital-Acquired Bloodstream Infection
title Development and Validation of a Prognostic Model for Multi-Drug-Resistant Non-Hospital-Acquired Bloodstream Infection
title_full Development and Validation of a Prognostic Model for Multi-Drug-Resistant Non-Hospital-Acquired Bloodstream Infection
title_fullStr Development and Validation of a Prognostic Model for Multi-Drug-Resistant Non-Hospital-Acquired Bloodstream Infection
title_full_unstemmed Development and Validation of a Prognostic Model for Multi-Drug-Resistant Non-Hospital-Acquired Bloodstream Infection
title_short Development and Validation of a Prognostic Model for Multi-Drug-Resistant Non-Hospital-Acquired Bloodstream Infection
title_sort development and validation of a prognostic model for multi-drug-resistant non-hospital-acquired bloodstream infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295786/
https://www.ncbi.nlm.nih.gov/pubmed/37370274
http://dx.doi.org/10.3390/antibiotics12060955
work_keys_str_mv AT pivettaemanuele developmentandvalidationofaprognosticmodelformultidrugresistantnonhospitalacquiredbloodstreaminfection
AT corcionesilvia developmentandvalidationofaprognosticmodelformultidrugresistantnonhospitalacquiredbloodstreaminfection
AT peassopaolo developmentandvalidationofaprognosticmodelformultidrugresistantnonhospitalacquiredbloodstreaminfection
AT carairene developmentandvalidationofaprognosticmodelformultidrugresistantnonhospitalacquiredbloodstreaminfection
AT capodannoalberto developmentandvalidationofaprognosticmodelformultidrugresistantnonhospitalacquiredbloodstreaminfection
AT brussinoandrea developmentandvalidationofaprognosticmodelformultidrugresistantnonhospitalacquiredbloodstreaminfection
AT petittipaolo developmentandvalidationofaprognosticmodelformultidrugresistantnonhospitalacquiredbloodstreaminfection
AT gallieleonora developmentandvalidationofaprognosticmodelformultidrugresistantnonhospitalacquiredbloodstreaminfection
AT galmozzimaddalena developmentandvalidationofaprognosticmodelformultidrugresistantnonhospitalacquiredbloodstreaminfection
AT ghisettivaleria developmentandvalidationofaprognosticmodelformultidrugresistantnonhospitalacquiredbloodstreaminfection
AT cavallorossana developmentandvalidationofaprognosticmodelformultidrugresistantnonhospitalacquiredbloodstreaminfection
AT aprafranco developmentandvalidationofaprognosticmodelformultidrugresistantnonhospitalacquiredbloodstreaminfection
AT lupiaenrico developmentandvalidationofaprognosticmodelformultidrugresistantnonhospitalacquiredbloodstreaminfection
AT derosafrancescogiuseppe developmentandvalidationofaprognosticmodelformultidrugresistantnonhospitalacquiredbloodstreaminfection
AT montrucchiogiuseppe developmentandvalidationofaprognosticmodelformultidrugresistantnonhospitalacquiredbloodstreaminfection